Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Popular Longevity Supplement Fails to Meet Endpoint in Parkinson's Trial

(MedPage Today) -- Nicotinamide riboside, a form of vitamin B3 that increases cellular levels of nicotinamide adenine dinucleotide (NAD+), had no significant clinical benefit in early Parkinson's disease, the NOPARK randomized trial showed. Commonly...

Popular Longevity Supplement Fails to Meet Endpoint in Parkinson's Trial

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Friday 9 October →